Tirzepatide 5mg
| Product Overview | |
| Generic Name | Tirzepatide 5mg |
| Brand Name(s) | Mounjaro, Zepbound |
| Form | 5 mg single-dose vial |
| Strength | 5 mg. / 0.5 mL, |
| Therapeutic Class | Dual GIP–GLP-1 receptor agonist for T2DM, obesity, and sleep apnea |
| ATC Code | A10BK04 |
| Manufacturing & Regulatory | |
| Manufacturer | Eli Lilly; API also sourced from Indian CDMOs |
| Country | India |
| GMP Compliance | WHO-GMP, API mfgs hold ISO/FDA certificates |
| DMF/CEP | DMFs via API suppliers (Type II) |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 24 Months |
| Storage | Refrigerated (2–8 °C) |
| Incoterms | FOB / CIF / DDP |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
A dual agonist of the GLP‑1 and glucose‑dependent insulinotropic polypeptide (GIP) receptors; simultaneous stimulation of both receptors synergistically amplifies insulinotropic effects, augments adipose‑tissue lipolysis, and further attenuates hunger signals, resulting in superior weight loss of up to 20 % of baseline body weight, surpassing the efficacy of selective GLP‑1 agonism.
Once-weekly injection for type 2 diabetes (as Mounjaro); obesity management and OSA (as Zepbound). Demonstrates marked reductions in HbA1c and weight (~15–20%) with favorable safety profile.
Also available in (2.5 mg, 7.5 mg, 10 mg, 12.5 mg & 15 mg. all in 0.5 mL)
